top of page

PAID ADS

​​​Background Info

Medable's decentralized clinical trial platform allows  trials to be run simultaneously in-person and remotely.

 

Their software brings more ease, equity, and precision to medical research by making it easier for: 
• patients to participate in medical research
• pharmaceutical companies and clinical trial sites to efficiently run studies

​

​

​​​

Challenge

Address clinical trial staffs' pain points of exclusively conducting in-person research to entice them to learn more about why decentralized trials will relieve their struggles

​

​

Solution

In addition to empathy, in the various ads, I used: 
• To establish Medable as a knowledge resource, I used:

  • industry language (for further explanation see 'details about ad language' below the images to the right)

• To establish trust that they are a reputable company, I used statistics such as:

  • '#1 in Everest PEAK matrix'

  • '#1 DCT platform'

  • 'built by clinicians, patients advocates, and tech experts'

​

​

​

Notable Outcome

Before introducing a new updating branding, my copy alone saw a 5x better performance than previously run ads

​

​

​

NOTE: Click on the images to enlarge them for better readability.

​

 

​

​

​

​

afe4e1150474085_edited.jpg
a81a33150474085.62fb1beea9151.png
d26650150474085.62fb1beea4b28.png
c5ef6a150474085.62fb1beea7d1f.png
27844e150474085.62fb1beea67b1.png

​

Ad Language Detail​

Patients wearing thin?

​Many studies get delayed, greatly increasing the cost of running the study, because they do not have enough participants sign up for the trial. A decentralized trial makes it easier for people to participate because they do not have to take extensive time out of their days—which is an excessive burden to low-income patients as well as those with serious medical conditions—to travel to a physical site to participate.​

 

Your patients have been patient long enough.

By running trials more efficiently and not having to wait for patients to physically visit a site, Medable's technology helps speed up the length of a clinical trial. This means that therapies (medicine or technology) can get approved faster and patients benefit from these therapies faster—in certain cases, saving their lives.​

 

1000+ patients a day helps keep the IRB revision away.

When a study fails to enroll enough patients, the study documents, such as the IRB, need to be revised—delaying the study timeline and making the study more costly to complete.​

 

We've been green lit.

Before a trial can officially begin, it goes through many stages of approval. When a study is 'green lit', that means that everything has been thoroughly vetted and approved, and the study can officially begin.

​

​

​

bottom of page